ClinicaliQ Trial Snapshot
- A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer — Active Not Recruiting • Phase III • Oncology • NCT06311721.
- Trial comparing a biosimilar copy of Keytruda with the original drug in advanced lung cancer patients to confirm equivalent effectiveness.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The primary objective of this study is to compare the efficacy of ABP 234 with the pembrolizumab reference product (Keytruda®). Conditions: Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Interventions: ABP 234, Pembrolizumab (US), Pembrolizumab (EU) Lead Sponsor: Amgen Planned Enrollment: 315 participants